长春高新子公司金赛药业与丹麦ALK达成变应原特异性免疫治疗产品合作

Group 1 - The core point of the article is that Changchun High-tech (000661) has entered into a collaboration with Danish company ALK-Abelló A/S to develop and commercialize allergen-specific immunotherapy (AIT) products in China [1] - Changchun Jin Sai Pharmaceutical, a subsidiary of Changchun High-tech, will have exclusive rights to three ALK-developed products in mainland China, including subcutaneous allergen preparations, skin prick test kits, and sublingual tablets [1] - The collaboration agreement grants Changchun Jin Sai Pharmaceutical exclusive rights until December 31, 2039, and involves an upfront payment of €32.7 million for the commercialization rights of the three products [1]